Johns Hopkins ABX Guide
Glecaprevir + Pibrentasvir
INDICATIONS
FDA
FDA
- Treatment of adult patients with chronic HCV infection (genotypes 1, 2, 3, 4, 5, or 6) without cirrhosis or compensated cirrhosis (Child-Pugh A).
- Treatment of adult patients with HCV Genotype 1 infection previously treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 10, 2018
Citation
Dzintars, Kathryn. "Glecaprevir + Pibrentasvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540688/2/Glecaprevir_+_Pibrentasvir.
Dzintars K. Glecaprevir + Pibrentasvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540688/2/Glecaprevir_+_Pibrentasvir. Accessed June 1, 2023.
Dzintars, K. (2018). Glecaprevir + Pibrentasvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540688/2/Glecaprevir_+_Pibrentasvir
Dzintars K. Glecaprevir + Pibrentasvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2023 June 01]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540688/2/Glecaprevir_+_Pibrentasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Glecaprevir + Pibrentasvir
ID - 540688
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/07/10/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540688/2/Glecaprevir_+_Pibrentasvir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
